Figure 3.
The mechanism of (A) DEX-HAase adjuvant and PD-L1 checkpoint enhancing PDT and anti-tumor immune response. (B) Evaluation of anti-tumor immunity in vivo. (B1) Schematic illustration of enhanced PDT and anti-PD-L1 combination therapy. In vivo results of (B2) primary and (B3) distant tumors growth curves of different groups of mice after various treatments. (B4) Morbidity-free survival of different groups of mice. (B5) CTL infiltration in tumors and (B6) the ratio of CD8+ T cells to regulatory T cells of mice post various treatments. B7) The production of TNF-α in serum of mice post various treatments. Adapted with permission from 37, copyright 2019 John Wiley and Sons.